SUTRO BIOPHARMA, INC. Increase (Decrease) in Contract with Customer, Liability
SUTRO BIOPHARMA, INC. (STRO) reported Increase (Decrease) in Contract with Customer, Liability of -$6.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$4.18M.
- SUTRO BIOPHARMA, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$1.96M.
- SUTRO BIOPHARMA, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$145.00K.
- SUTRO BIOPHARMA, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$6.13M.
- SUTRO BIOPHARMA, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$69.73M, a 988.83% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was $7.84M.
- SUTRO BIOPHARMA, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$32.60M, a 134.81% decline from fiscal 2022.
- SUTRO BIOPHARMA, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was $93.65M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$6.13M 10-Q · filed 2026-08-12 | -$6.28M derived: sum of 3 quarters · filed 2026-08-12 | -$12.41M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$1.96M 10-Q · filed 2026-05-14 | -$2.10M derived: sum of 2 quarters · filed 2026-05-14 | -$8.24M derived: sum of 3 quarters · filed 2026-05-14 | -$66.91M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$6.28M derived: sum of 2 quarters · filed 2026-03-23 | -$64.95M derived: sum of 3 quarters · filed 2026-08-12 | -$69.73M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$6.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$64.81M derived: sum of 2 quarters · filed 2026-08-12 | -$69.58M 10-Q · filed 2025-11-06 | -$77.82M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$58.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$63.45M 10-Q · filed 2026-08-12 | -$71.69M derived: sum of 3 quarters · filed 2026-08-12 | -$76.78M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$4.78M 10-Q · filed 2026-05-14 | -$13.02M derived: sum of 2 quarters · filed 2026-05-14 | -$18.11M derived: sum of 3 quarters · filed 2026-05-14 | $10.30M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$8.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$13.34M derived: sum of 2 quarters · filed 2026-03-23 | $15.07M derived: sum of 3 quarters · filed 2026-03-23 | $7.84M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$5.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $23.32M derived: sum of 2 quarters · filed 2025-11-06 | $16.09M 10-Q · filed 2025-11-06 | -$12.01M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $28.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $21.18M 10-Q · filed 2025-08-07 | -$6.91M derived: sum of 3 quarters · filed 2025-08-07 | -$2.69M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$7.23M 10-Q · filed 2025-05-08 | -$35.32M derived: sum of 2 quarters · filed 2025-05-08 | -$31.10M derived: sum of 3 quarters · filed 2025-05-08 | -$35.42M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$28.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$23.87M derived: sum of 2 quarters · filed 2025-03-13 | -$28.19M derived: sum of 3 quarters · filed 2025-03-13 | -$32.60M 10-K · filed 2025-03-13 |
| 2023-09-30 | $4.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$95.00K derived: sum of 2 quarters · filed 2024-11-13 | -$4.51M 10-Q · filed 2024-11-13 | $3.98M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | -$4.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$8.73M 10-Q · filed 2024-08-13 | -$236.00K derived: sum of 3 quarters · filed 2025-03-13 | -$6.07M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | -$4.41M 10-Q · filed 2024-05-13 | $4.08M derived: sum of 2 quarters · filed 2025-03-13 | -$1.76M derived: sum of 3 quarters · filed 2025-03-13 | $88.45M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $8.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $2.65M derived: sum of 2 quarters · filed 2025-03-13 | $92.86M derived: sum of 3 quarters · filed 2025-03-13 | $93.65M 10-K · filed 2025-03-13 |
| 2022-09-30 | -$5.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $84.37M derived: sum of 2 quarters · filed 2023-11-13 | $85.16M 10-Q · filed 2023-11-13 | $82.70M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | $90.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $90.99M 10-Q · filed 2023-08-10 | $88.54M derived: sum of 3 quarters · filed 2024-03-25 | $88.17M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | $783.00K 10-Q · filed 2023-05-15 | -$1.67M derived: sum of 2 quarters · filed 2024-03-25 | -$2.04M derived: sum of 3 quarters · filed 2024-03-25 | -$6.63M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | -$2.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$2.83M derived: sum of 2 quarters · filed 2024-03-25 | -$7.41M derived: sum of 3 quarters · filed 2024-03-25 | -$15.21M 10-K · filed 2024-03-25 |
| 2021-09-30 | -$372.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$4.96M derived: sum of 2 quarters · filed 2022-11-08 | -$12.75M 10-Q · filed 2022-11-08 | -$16.12M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-06-30 | -$4.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$12.38M 10-Q · filed 2022-08-08 | -$15.75M derived: sum of 3 quarters · filed 2023-03-30 | -$25.74M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-03-31 | -$7.79M 10-Q · filed 2022-05-09 | -$11.16M derived: sum of 2 quarters · filed 2023-03-30 | -$21.16M derived: sum of 3 quarters · filed 2023-03-30 | -$25.08M derived: sum of 4 quarters · filed 2023-03-30 |
| 2020-12-31 | -$3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$13.36M derived: sum of 2 quarters · filed 2023-03-30 | -$17.28M derived: sum of 3 quarters · filed 2023-03-30 | -$14.96M 10-K · filed 2023-03-30 |
| 2020-09-30 | -$10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$13.92M derived: sum of 2 quarters · filed 2021-11-10 | -$11.59M 10-Q · filed 2021-11-10 | -$16.03M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$3.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$1.59M 10-Q · filed 2021-08-09 | -$6.03M derived: sum of 3 quarters · filed 2022-02-28 | -$12.89M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $2.33M 10-Q · filed 2021-05-07 | -$2.11M derived: sum of 2 quarters · filed 2022-02-28 | -$8.97M derived: sum of 3 quarters · filed 2022-02-28 | -$12.56M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$4.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$11.30M derived: sum of 2 quarters · filed 2022-02-28 | -$14.88M derived: sum of 3 quarters · filed 2022-02-28 | -$20.19M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$6.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$10.45M derived: sum of 2 quarters · filed 2020-11-05 | -$15.75M 10-Q · filed 2020-11-05 | -$22.61M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | -$3.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$8.89M 10-Q · filed 2020-08-06 | -$15.75M derived: sum of 3 quarters · filed 2021-03-18 | $38.74M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | -$5.30M 10-Q · filed 2020-05-11 | -$12.16M derived: sum of 2 quarters · filed 2021-03-18 | $42.33M derived: sum of 3 quarters · filed 2021-03-18 | $39.66M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | -$6.86M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $47.63M derived: sum of 2 quarters · filed 2021-03-18 | $44.96M derived: sum of 3 quarters · filed 2021-03-18 | $42.30M 10-K · filed 2021-03-18 |
| 2018-09-30 | $54.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $51.82M derived: sum of 2 quarters · filed 2019-11-08 | $49.17M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | -$2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$5.32M 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | -$2.66M 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | -$25.57M 10-K · filed 2020-03-16 | |||
| 2016-12-31 | -$23.12M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |